Current and emerging management options for Clostridium difficile infection: What is the role of fidaxomicin?

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL.6, 2012, Pages 28-35

  Cornely, O A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antibiotics; C. difficile; C.difficile infection; Fidaxomicin; Vancomycin

Indexed keywords

CADAZOLID; FIDAXOMICIN; FUSIDIC ACID; METRONIDAZOLE; NITAZOXANIDE; RAMOPLANIN; RIFAMYCIN; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; DISEASE SEVERITY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW;

EID: 84868576303     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12012     Document Type: Review

References (40)

1. Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46: 1489-1492.
2. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-1079.
3. Hedge DD, Strain JD, Heins JR, Farver DK. New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag 2008; 4: 949-964.
4. Koo HL, Garey KW, DuPont HL. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs 2010; 19: 825-836.
5. Zar FA, Bakkanagari SR, Moorthi SR, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
6. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1): S32-S42.
7. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775.
8. Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
9. Louie TJ, Miller MA, Mullane KM et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431.
10. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-1918.
11. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549-557.
12. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-1052.
13. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nature Rev Microbiol 2009; 7: 526-536.
14. DuPont HL. The search for effective treatment of Clostridium difficile infection. N Engl J Med 2011; 364: 473-474.
15. Wenisch JM, Schmid D, Kuo HW et al. Prospective observational study comparing three different treatment regimens in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56: 1974-1978.
16. Huhulescu S, Sagel U, Fiedler A et al. Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. J Med Microbiol 2011; 60: 1206-1212.
17. Cohen MB. Clostridium difficile infections: emerging epidemiology and new treatments. J Ped Gastroenterol Nutr 2009; 48: 63-65.
18. Bauer MP, Notermans DW, van Benthem BH et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377: 63-73.
19. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-193.
20. Hu MY, Katchar K, Kyne L et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136: 1206-1214.
21. Pépin J, Alary M-E, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 1591-1597.
22. Babakhani F, Gomez A, Robert N et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60: 1213-1217.
23. Louie TJ, Emery J, Krulicki W et al. OPT-80 Eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-263.
24. Tannock GW, Munro K, Taylor C et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156: 3354-3359.
25. Babakhani F, Gomez A, Robert N et al. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 2011; 55: 4427-4429.
26. Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 2011; 9: 767-777.
27. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection?Clin Infect Dis 1997; 25 (Suppl 2): S206-S210.
28. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment report for DIFICLIR (fidaxomicin), 22 September 2011; EMA/857570/2011. London, UK.
29. Shue YK, Sears PS, Shangle S et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008; 52: 1391-1395.
30. Cornely OA, Crook DW, Esposito R et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-289.
31. Crook DW, Walker AS, Kean Y et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55 (Suppl 2): S93-S103.
32. Petrella LA, Sambol SP, Cheknis A et al. Decreased cure rate and increased recurrence rate for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012; 55: 351-357.
33. Cornely OA, Miller M, Louie TA, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55 (Suppl 2): S154-S161.
34. Mullane KM, Miller MA, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in patients taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440-447.
35. Cunney RJ, Magee C, McNamara E et al. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant 1998; 13: 2842-2846.
36. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-1172.
37. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician 2005; 71: 921-928.
38. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-1087.
39. Kyne L, Warny M, Qamar A, Kelly C. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
40. McFarland LV. Alternative treatment for Clostridium difficile disease: what really works?J Med Microbiol 2005; 54: 101-111.